Meeting NewsVideo

VIDEO: Entyvio shows superiority in ulcerative colitis

SAN DIEGO — In this exclusive video from Digestive Disease Week, Bruce Sands, MD, from Icahn School of Medicine at Mount Sinai, discusses findings from the VARSITY study, the first head-to-head trial comparing biologic therapies for ulcerative colitis.

“We were comparing adalimumab [Humira, AbbVie], an anti-TNF antibody, to vedolizumab [Entyvio, Takeda], which is an anti-alpha 4 beta 7 integrin antibody, in patients with ulcerative colitis,” Sands told Healio Gastroenterology and Liver Disease. “These are two widely used treatments for ulcerative colitis, but the two have never been compared head-to-head in a randomized controlled fashion.”

The VARSITY study was a 52-week double-dummy, blinded study. Earlier this year, Sands presented Data that showed vedolizumab was superior in terms of achieving clinical remission at week 52.

At DDW, Sands presented additional data on histologic remission at week 52. Histologic outcomes were also superior in vedolizumab.

“We think this is an important study,” Sands said. “It helps us understand where to position these drugs in relation to each other.”

Reference:

Sands BE, et al. Abstract 426a. Presented at: Digestive Disease Week; May 18-21, 2019; San Diego.

Disclosure: Sands reports financial support for research from Celgene, Janssen, Pfizer and Takeda.

SAN DIEGO — In this exclusive video from Digestive Disease Week, Bruce Sands, MD, from Icahn School of Medicine at Mount Sinai, discusses findings from the VARSITY study, the first head-to-head trial comparing biologic therapies for ulcerative colitis.

“We were comparing adalimumab [Humira, AbbVie], an anti-TNF antibody, to vedolizumab [Entyvio, Takeda], which is an anti-alpha 4 beta 7 integrin antibody, in patients with ulcerative colitis,” Sands told Healio Gastroenterology and Liver Disease. “These are two widely used treatments for ulcerative colitis, but the two have never been compared head-to-head in a randomized controlled fashion.”

The VARSITY study was a 52-week double-dummy, blinded study. Earlier this year, Sands presented Data that showed vedolizumab was superior in terms of achieving clinical remission at week 52.

At DDW, Sands presented additional data on histologic remission at week 52. Histologic outcomes were also superior in vedolizumab.

“We think this is an important study,” Sands said. “It helps us understand where to position these drugs in relation to each other.”

Reference:

Sands BE, et al. Abstract 426a. Presented at: Digestive Disease Week; May 18-21, 2019; San Diego.

Disclosure: Sands reports financial support for research from Celgene, Janssen, Pfizer and Takeda.

    See more from Digestive Disease Week